Jean Hynes of the Vanguard Health Care Fund added to her stake in UCB (XBRU:UCB, Financial) during the second quarter at an average price of €66.98 euros ($74.26) per share. The trade had a 0.1% impact on Hynes portfolio. She now owns 11,342,503 shares of the company.
Union Chimique Belge (UCB) was established by Emmanuel Janssen in Brussels, Belgium in 1928, primarily focusing on industrial chemicals. It was one of the first companies in the world to distil ammonia from coal. Since then the company has been expanding its operations. It is currently engaged in the discovery and development of medicines in the fields of oncology, central nervous system disorders such as epilepsy, diabetic neuropathic pain, and immunology disorders such as allergies and arthritis.
UCB has a market cap of €13.17 billion, a P/E ratio of 19.50, an enterprise value of €14.12 billion and a P/B ratio of 2.44.
According to GuruFocus, UCB has a 6 of 10 financial rating and a 7 of 10 profitability and growth rating, with an operating margin of 14.81%.Â
UCB has four good signs according to GuruFocus, which may have influenced Hynes' decision to add to her stake in the company during the second quarter:
- The company’s operating margin is expanding.
- The dividend yield is close to a two-year high.
- The company's P/E ratio is close to a five-year low of 20.24.
- The company’s P/S ratio is 3.42, which is close to its two-year low of 3.15.
Below is a Peter Lynch Chart that shows UCB is trading above its intrinsic value.
Since its inception, the Vanguard Health Care Fund (Trades, Portfolio) has returned an estimated 17.4% annually.
Cheers to your investment success.
Disclosure: Author does not own any shares of this company.
